NELFCD and neoplasm: This provides justification for additional clinical trials that will include the pairing of lapatinib with anti-HER-2 DC1 immunization to enhance responsiveness to vaccine therapy, and furthermore encourages the continued search for additional agents that work cooperatively with Th1 cytokines to enhance tumor killing.